IFNG and chronic myelogenous leukemia, BCR-ABL1 positive: The ability of BET inhibitors, such as JQ1, to suppress constitutive or IFN‐γ induced PD‐L1 expression in certain cancer cell lines as well as stem cells of chronic myeloid leukemia patients were previously described.52, 53